started · updated
Celltrion's Omlyclo expands in Europe with 90% market share in Spain
Celltrion is expanding the market presence of its omaliizumab biosimilar, Omlyclo, across 26 European countries. The company reported significant early success in Southern Europe, noting that Omlyclo's market share in Spain exceeded 90% as of July. Additionally, sales performance in Italy has surpassed the company's initial business targets.
To bolster its presence, Celltrion participated in the European Respiratory Society (ERS) Congress held in Barcelona. During the event, the company highlighted Omlyclo's competitive advantages, including its diverse dosage options (75mg, 150mg, and 300mg) and various administration devices such as pre-filled syringes and auto-injectors. The product is designed for treating allergic asthma and chronic spontaneous urticaria.
Celltrion intends to build on this momentum by increasing participation in national tenders and strengthening direct sales networks with medical institutions across Europe. The company also plans to attend the Global Urticaria Forum 2026 in Berlin to expand its reach into skin disease treatment areas.
Entities
Celltrion · European Respiratory Society · Omlyclo · Roland Buhl · Spain
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 2 SOURCES] The product is offered via pre-filled syringes and auto-injectors. www.biotimes.co.kr · biz.heraldcorp.com
- [● 3 SOURCES] Omlyclo's market share in Spain exceeded 90% as of July. www.biotimes.co.kr · kormedi.com · biz.heraldcorp.com
- [● 3 SOURCES] Sales in Italy have exceeded initial business targets. www.biotimes.co.kr · kormedi.com · biz.heraldcorp.com
- [● 2 SOURCES] Celltrion plans to participate in the Global Urticaria Forum 2026 in Berlin. www.biotimes.co.kr · biz.heraldcorp.com
- [● 3 SOURCES] Omlyclo is currently being sold in 26 European countries. www.biotimes.co.kr · kormedi.com · biz.heraldcorp.com
- [● 3 SOURCES] Omlyclo is available in 75mg, 150mg, and 300mg dosages. www.biotimes.co.kr · kormedi.com · biz.heraldcorp.com
- [● 3 SOURCES] Celltrion participated in the European Respiratory Society Congress in Barcelona. www.biotimes.co.kr · kormedi.com · biz.heraldcorp.com
- [● 2 SOURCES] Omlyclo is a biosimilar of Xolair used for allergic asthma and chronic spontaneous urticaria. kormedi.com · biz.heraldcorp.com